222. Primary nephrotic syndrome Clinical trials / Disease details

Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TRC-14005064	2014-09-01	2014-08-06	A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stage	Investigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis	chronic kidney disease	1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ;	Shanghai University of T.C.M	NULL	Recruiting	18	60	Both	1:50;2:50;		China
2	NCT01845688 (ClinicalTrials.gov)	November 2011	29/4/2013	Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy	Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study	Idiopathic Membranous Nephropathy	Drug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo Granule	wanglin	NULL	Active, not recruiting	18 Years	70 Years	Both	72	N/A	China
3	NCT00814255 (ClinicalTrials.gov)	December 2008	22/12/2008	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	Novel Therapies for Resistant Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	Drug: Adalimumab;Drug: Lisinopril , losartan, and atorvastatin;Drug: galactose	New York University School of Medicine	University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	1 Year	65 Years	All	32	Phase 2	United States;Canada